

Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments

Juan Tamargo

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, CIBERCV, Madrid, Spain

Citation: *European Cardiology Review* 2019;14(3):201. **DOI:** <https://doi.org/10.15420/ecr.2019.14.3.CG1>


Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

In the article by Juan Tamargo entitled Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments (*European Cardiology Review* 2019;14(1):23–32. <https://doi.org/10.15420/ecr.2018.34.2>), the following correction should be made:

Figure 1 should indicate an increase (↑) in haemoglobin and haematocrit, not a decrease (↓). The corrected figure appears below.

The author apologises for this error. ■

Figure 1: Potential Mechanisms Involved in the Cardioprotective and Renoprotective Effects of Sodium–glucose Cotransporter 2 Inhibitors



BHOB = 3-beta-hydroxybutyrate; FA = fatty acid; HHF = hospitalisations for HF; MACE = major adverse cardiovascular events; NHE = Na–H– exchanger; P/O = ATP yield per oxygen atom consumed of oxidative phosphorylation; SGLT2 = sodium–glucose cotransporter 2; TG = tubuloglomerular.